## SYK: Stryker Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -5.4% below STRENGTH zone (4.0-10.0%); PEG 1.86 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($339.08)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Should Strykerâ€™s (SYK) New Internal Leadership Team Redefine Expectations Around Execution And Innovation?**
- Source: Simply Wall Street | 20251209T062138 | Somewhat-Bullish | Relevance: 99%
-  Stryker Corporation has announced key leadership changes, with Spencer Stiles becoming President and COO, and Dylan Crotty promoted to Group President of Orthopaedics, effective January 1, 2026. These internal promotions emphasize continuity and succession planning, which will influence the company's growth, innovation, and global expansion strategies. Investors should consider how this leadership team will sustain Stryker's growth profile amidst rising R&D and compliance costs, particularly in light of the company's upsized 2025 organic net sales growth outlook.

**2. SVB Wealth LLC Makes New $4.79 Million Investment in Stryker Corporation $SYK**
- Source: MarketBeat | 20251208T123542 | Somewhat-Bullish | Relevance: 98%
-  SVB Wealth LLC has initiated a new investment of $4.79 million in Stryker Corporation (NYSE:SYK) by purchasing 12,095 shares during the second quarter. This new stake comes alongside significant insider selling, with Director Ronda E. Stryker selling shares worth $97.6 million and other insiders selling a total of $185.4 million in the last 90 days. Despite insider sales, analysts maintain a "Moderate Buy" rating for Stryker, with a consensus target price of $433.78, following the company's Q3 earnings beat and positive FY2025 EPS guidance.

**3. Winslow Capital Management LLC Sells 11,858 Shares of Stryker Corporation $SYK**
- Source: MarketBeat | 20251208T125942 | Neutral | Relevance: 98%
-  Winslow Capital Management LLC reduced its stake in Stryker Corporation by 1.2% in the second quarter, selling 11,858 shares and now owning 964,432 shares valued at approximately $381.6 million. This reduction follows significant insider selling, with company insiders offloading 522,118 shares worth roughly $185.4 million in the last 90 days. Despite the institutional selling, Stryker recently surpassed quarterly earnings estimates, reported strong revenue growth, and holds a "Moderate Buy" analyst rating with an average target price of $433.78.

**4. State Street Corp Increases Stake in Stryker Corporation $SYK**
- Source: MarketBeat | 20251209T134902 | Somewhat-Bullish | Relevance: 98%
-  State Street Corp increased its stake in Stryker Corporation (NYSE:SYK) by 1.0% during the second quarter, now owning 3.91% of the company's stock valued at over $5.9 billion. Other institutional investors have also adjusted their positions, and analysts generally rate Stryker as a "Moderate Buy" with an average target price of $433.78. Recent insider transactions show executives selling shares.

**5. Natixis Has $35.77 Million Position in Stryker Corporation $SYK**
- Source: MarketBeat | 20251208T122742 | Somewhat-Bullish | Relevance: 97%
-  Natixis significantly increased its stake in Stryker Corporation, boosting its holdings by 50.5% to 90,408 shares valued at $35.77 million. This comes as Stryker reported strong quarterly results with better-than-expected EPS and revenue, setting a positive outlook for FY2025. Despite substantial insider selling in the last 90 days, institutional ownership remains high at 77.1%, and analysts maintain a "Moderate Buy" rating for the medical technology company.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-14 | Truist Securiti | $400 | $392 | +2% |
| 2025-11-14 | Wells Fargo | $456 | $452 | +1% |
| 2025-11-14 | Needham | $448 | $448 | 0% |
| 2025-11-14 | BTIG | $410 | $410 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-14 | Truist Securiti | main | Hold |
| 2025-11-14 | Wells Fargo | main | Overweight |
| 2025-11-14 | Needham | reit | Buy |
| 2025-11-14 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 6 ($34.68M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (+0.8%)
- Blackrock Inc.: 7.0% (+0.4%)
- JPMORGAN CHASE & CO: 6.2% (+95.3%)
- Greenleaf Trust: 4.3% (-0.3%)
- State Street Corpora: 3.9% (-0.1%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.1% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $35M sold (6 transactions in 90 days).
3. Long-term trend broken: trading 6.1% below SMA200.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.86 elevated, pricing in significant growth expectations. Forward P/E 23.7x stretched relative to 10% growth. Balance sheet: $1.4B free cash flow. Insider selling cluster ($34.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $135.3B |
| Beta | 0.90 |
| 52W Range | $329.16 - $406.19 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.86 |
| Forward P/E | 23.7 |
| Current P/E | 26.1 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -2.3% to -5.4% (-3.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 9.4pp (needs >4.0% for momentum thesis). Below SMA200 (0.94x), long-term trend not supportive. MACD histogram bearish (-1.61), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -5.37% (CS: 14) | Weak |
| RSI_14 | 39.8 | Neutral |
| MACD Histogram | -1.61 | Bearish |
| vs SMA20 | 0.970x | Below |
| vs SMA50 | 0.963x | Below |
| vs SMA200 | 0.939x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $353.80
- **Stop Loss:** $339.08 (4.2% risk)
- **Target:** $368.52 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 33
- **Position Value:** $11,675.40
- **Portfolio %:** 11.68%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-01-27 (Est: $4.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.13 | $3.19 | +1.9% |
| 2025Q2 | $3.07 | $3.13 | +1.9% |
| 2025Q1 | $2.73 | $2.84 | +4.0% |
| 2024Q4 | $3.87 | $4.01 | +3.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*